Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BTMD Stock Forecast 2025-2026
$4.08
Current Price
$200.03M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BTMD Price Targets
+96.1%
To High Target of $8.00
+71.3%
To Median Target of $6.99
-2.0%
To Low Target of $4.00
BTMD Price Momentum
+2.3%
1 Week Change
+7.9%
1 Month Change
-49.6%
1 Year Change
-34.0%
Year-to-Date Change
-51.7%
From 52W High of $8.44
+34.2%
From 52W Low of $3.04
📊 TOP ANALYST CALLS
Did BTMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Biote is one of their latest high-conviction picks.
Latest BTMD Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, BTMD has a bullish consensus with a median price target of $6.99 (ranging from $4.00 to $8.00). Currently trading at $4.08, the median forecast implies a 71.3% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Alex Fuhrman at Craig-Hallum, projecting a 96.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BTMD Analyst Ratings
5
Buy
0
Hold
0
Sell
BTMD Price Target Range
Low
$4.00
Average
$6.99
High
$8.00
Current: $4.08
Latest BTMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BTMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | Craig-Hallum | Alex Fuhrman | Buy | Maintains | $8.00 |
| Dec 16, 2024 | Craig-Hallum | Alex Fuhrman | Buy | Initiates | $12.00 |
| Mar 13, 2024 | Roth MKM | George Kelly | Buy | Reiterates | $9.00 |
| Feb 20, 2024 | B. Riley Securities | Jeff Van Sinderen | Buy | Initiates | $9.00 |
| Feb 1, 2024 | Jefferies | Kaumil Gajrawala | Buy | Initiates | $6.55 |
| Jan 18, 2024 | Truist Securities | Gregory Fraser | Buy | Maintains | $9.00 |
| Jan 18, 2024 | Roth MKM | George Kelly | Buy | Maintains | $7.00 |
| Aug 15, 2023 | TD Cowen | Brian Holland | Outperform | Maintains | $7.00 |
| Aug 14, 2023 | Roth MKM | George Kelly | Buy | Reiterates | $12.00 |
| Mar 30, 2023 | Roth MKM | George Kelly | Buy | Maintains | $11.00 |
| Sep 27, 2022 | Truist Securities | Gregory Fraser | Buy | Initiates | $10.00 |
| Jun 24, 2022 | Cowen & Co. | Brian Holland | Outperform | Initiates | $11.00 |
| Jun 23, 2022 | Roth Capital | George Kelly | Buy | Initiates | $9.00 |
Biote Corp. (BTMD) Competitors
The following stocks are similar to Biote based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biote Corp. (BTMD) Financial Data
Biote Corp. has a market capitalization of $200.03M with a P/E ratio of 7.0x. The company generates $199.38M in trailing twelve-month revenue with a 10.6% profit margin.
Revenue growth is +4.7% quarter-over-quarter, while maintaining an operating margin of +19.8% and return on equity of -3.1%.
Valuation Metrics
Market Cap
$200.03M
Enterprise Value
$199.41M
P/E Ratio
7.0x
PEG Ratio
7.0x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
+4.7%
Gross Margin
+74.3%
Operating Margin
+19.8%
Net Margin
+10.6%
EPS Growth
+4.7%
Financial Health
Cash/Price Ratio
+32.5%
Current Ratio
1.4x
Debt/Equity
-1.3x
ROE
-3.1%
ROA
+16.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Biote Corp. (BTMD) Business Model
About Biote Corp.
What They Do
Provides bioidentical hormone replacement therapy.
Business Model
Biote Corp. generates revenue by offering hormone optimization therapies, particularly through its innovative pellet therapy. The company also educates healthcare providers to implement these therapies effectively, creating a dual revenue stream from both direct treatment services and training programs.
Additional Information
The company focuses on personalized health solutions, catering to wellness, anti-aging, and preventive medicine. Its services align with the trend of personalized medicine, making it a key player in the biotechnology and healthcare sectors, with promising growth potential driven by the demand for innovative health solutions.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
217
CEO
Mr. Bret Christensen
Country
United States
IPO Year
2022
Website
www.biote.comBiote Corp. (BTMD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Is biote Corp. (BTMD) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jul 08, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Zacks emphasizes its Rank system based on earnings estimates and revisions, while also monitoring value, growth, and momentum trends to identify strong stock picks.
Why It Matters
Zacks' emphasis on earnings estimates and revisions signals potential stock performance, aiding investors in identifying promising growth and value opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Biote Names Rich Barrera to Board of Directors
1 month ago
Quick Summary
Biote Corp. (NASDAQ: BTMD) has appointed Rich Barrera to its Board of Directors, effective immediately, enhancing its leadership with his investment expertise.
Why It Matters
The election of Rich Barrera to Biote's Board enhances its leadership with investment expertise, potentially improving strategic decisions and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
biote Corp. (BTMD) Q1 2025 Earnings Call Transcript
2 months ago
Quick Summary
Biote Corp. (NASDAQ: BTMD) will hold its Q1 2025 earnings call on May 7, 2025, at 5:00 PM ET, featuring key executives and analysts from various financial firms.
Why It Matters
The Q1 2025 earnings call provides insights into biote Corp.'s financial health and strategic direction, crucial for assessing investment potential and market performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Biote Reports First Quarter 2025 Financial Results
2 months ago
Quick Summary
Biote (NASDAQ: BTMD) reported positive first-quarter results for 2025, driven by efficiencies from its 503B manufacturing facility and growth in dietary supplements.
Why It Matters
Biote's Q1 results highlight operational efficiencies and growth in dietary supplements, indicating strong performance and potential for continued profitability, which could attract investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Biote Corp. (BTMD) reported quarterly earnings of $0.08 per share, surpassing estimates of $0.06, but down from $0.23 per share year-over-year.
Why It Matters
Biote Corp. beat earnings expectations, indicating positive momentum, but a drop from last year's earnings raises concerns about growth sustainability.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Biote Corp. (Nasdaq: BTMD) will release its Q1 financial results on May 7, 2025, after market close, followed by a conference call at 5:00 p.m. ET.
Why It Matters
Biote Corp.'s upcoming financial results and conference call will provide insights into its performance and growth in the preventive health sector, influencing investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About BTMD Stock
What is Biote Corp.'s (BTMD) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Biote Corp. (BTMD) has a median price target of $6.99. The highest price target is $8.00 and the lowest is $4.00.
Is BTMD stock a good investment in 2026?
According to current analyst ratings, BTMD has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BTMD stock?
Wall Street analysts predict BTMD stock could reach $6.99 in the next 12 months. This represents a 71.3% increase from the current price of $4.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biote Corp.'s business model?
Biote Corp. generates revenue by offering hormone optimization therapies, particularly through its innovative pellet therapy. The company also educates healthcare providers to implement these therapies effectively, creating a dual revenue stream from both direct treatment services and training programs.
What is the highest forecasted price for BTMD Biote Corp.?
The highest price target for BTMD is $8.00 from Alex Fuhrman at Craig-Hallum, which represents a 96.1% increase from the current price of $4.08.
What is the lowest forecasted price for BTMD Biote Corp.?
The lowest price target for BTMD is $4.00 from at , which represents a -2.0% decrease from the current price of $4.08.
What is the overall BTMD consensus from analysts for Biote Corp.?
The overall analyst consensus for BTMD is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.99.
How accurate are BTMD stock price projections?
Stock price projections, including those for Biote Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2025 2:22 AM UTC